《大行報告》瑞銀升藥明巨諾-B(02126.HK)評級至「買入」 目標價下調至42.2元
瑞銀發表報告指,藥明巨諾-B(02126.HK)去年錄虧損16.64億元人民幣,較2019年的虧損6.33億元人民幣有所擴大,主要是由於優先股及認股證公平值變動、研發開支增加,及基於股份的薪酬提高。若撇除非持續項目的影響,去年經調整虧損3.04億元人民幣,對比2019年為虧損1.89億元人民幣。
該行表示,藥明巨諾-B(02126.HK)股價已較2月底的高位回調約40%,相信已完全反映來自零風險收益率(risk-free rate)上升的波動,及投資者對早期生物製藥企業的擔心。
瑞銀上調藥明巨諾股份評級,由「中性」升至「買入」,目標價由51.7元下調至42.2元,相信集團目前的風險回報吸引。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.